KRT17P2: A Potential Drug Target and Biomarker (G339241)
KRT17P2: A Potential Drug Target and Biomarker
Keratin 17 (K17) is a protein that plays a crucial role in the structure and function of hair. It is a large transmembrane protein that contains multiple domains, including an extracellular domain (ECD), a transmembrane domain (TMD), and an intracellular domain (ICD). K17 is expressed in a variety of tissues, including scalp, skin, and hair, and is involved in numerous cellular processes, including cell growth, differentiation, and signaling.
Recent studies have identified K17 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the potential of K17 as a drug target and biomarker, and discuss recent research on its role in these areas.
K17 as a Drug Target
K17 has been identified as a potential drug target due to its involvement in several cellular processes that are associated with various diseases. One of the key reasons for its potential as a drug target is its involvement in cell signaling pathways. K17 has been shown to be involved in several signaling pathways that are involved in cellular processes that are associated with the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
For example, K17 has been shown to be involved in the regulation of cell growth and differentiation. K17 has been shown to play a role in the regulation of cell cycle progression, and has been shown to interact with several transcription factors, including nuclear factor (NF) -kappa-B, which is involved in the regulation of cellular processes that are associated with the development and progression of cancer.
K17 has also been shown to be involved in the regulation of cell survival and apoptosis. K17 has been shown to play a role in the regulation of cell survival and apoptosis, and has been shown to interact with several stress-responsive pathways, including the unfoldasome-associated protein (FAP) signaling pathway.
In addition to its involvement in cellular signaling pathways, K17 has also been shown to be involved in the regulation of skin and hair growth and development. K17 has been shown to play a role in the regulation of skin and hair growth and development, and has been shown to interact with several transcription factors, including Dazl (Dazl gene 1), which is involved in the regulation of skin and hair growth and development.
K17 as a Biomarker
In addition to its potential as a drug target, K17 has also been shown to be a potential biomarker for several diseases. For example, K17 has been shown to be involved in the regulation of skin and hair growth and development, which could make it an attractive biomarker for diseases associated with these processes, such as cancer, neurodegenerative diseases, and autoimmune disorders.
K17 has also been shown to be involved in the regulation of cell survival and apoptosis, which could make it an attractive biomarker for diseases associated with these processes, such as neurodegenerative diseases and cancer. In addition, K17 has been shown to play a role in the regulation of cell cycle progression, which could make it an attractive biomarker for diseases associated with cellular processes that are associated with the development and progression of these diseases.
Recent Studies
Recent studies have further demonstrated the potential of K17 as a drug target and biomarker. For example, researchers have shown that inhibiting the activity of K17 can lead to the growth arrest and apoptosis of cancer cells. This suggests that K17 may be an attractive drug target for cancer treatment.
In addition, researchers have also shown that K17 is involved in the regulation of
Protein Name: Keratin 17 Pseudogene 2
The "KRT17P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRT17P2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
KRT17P3 | KRT17P5 | KRT17P7 | KRT18 | KRT18P1 | KRT18P12 | KRT18P13 | KRT18P16 | KRT18P17 | KRT18P19 | KRT18P22 | KRT18P23 | KRT18P24 | KRT18P27 | KRT18P28 | KRT18P29 | KRT18P31 | KRT18P33 | KRT18P34 | KRT18P4 | KRT18P40 | KRT18P41 | KRT18P42 | KRT18P44 | KRT18P48 | KRT18P49 | KRT18P5 | KRT18P50 | KRT18P51 | KRT18P55 | KRT18P59 | KRT18P6 | KRT18P62 | KRT19 | KRT19P2 | KRT19P3 | KRT2 | KRT20 | KRT222 | KRT23 | KRT24 | KRT25 | KRT26 | KRT27 | KRT28 | KRT3 | KRT31 | KRT32 | KRT33A | KRT33B | KRT34 | KRT35 | KRT36 | KRT37 | KRT38 | KRT39 | KRT4 | KRT40 | KRT42P | KRT5 | KRT6A | KRT6B | KRT6C | KRT7 | KRT7-AS | KRT71 | KRT72 | KRT73 | KRT73-AS1 | KRT74 | KRT75 | KRT76 | KRT77 | KRT78 | KRT79 | KRT8 | KRT80 | KRT81 | KRT82 | KRT83 | KRT84 | KRT85 | KRT86 | KRT87P | KRT89P | KRT8P10 | KRT8P11 | KRT8P12 | KRT8P14 | KRT8P16 | KRT8P17 | KRT8P18 | KRT8P22 | KRT8P23 | KRT8P25 | KRT8P26 | KRT8P29 | KRT8P3 | KRT8P33 | KRT8P36
